April 22, 2019
GEXVal Appeared in Nikkei, Japan's Largest Financial Paper
In an article highlighting the potential in existing drugs and the opportunity in repurposing, GEXVal was sighted as one of the companies leading the way. In a piece entitled “Using AI To Discover New Effects Of Old Drugs” published in Nikkei, 22th April 2019, GEXVal a spinout company from the Takeda repurposing initiative was sighted as example of the new breed of company attempting to combine the worlds of repurposing, artificial intelligence (AI) and rare diseases. “These are really exciting times where there are now many different ways to identify and test new drugs. Repurposing brings different challenges but also huge opportunity to bring new treatments to patients with rare diseases in an intelligent and cost-effective way. We have a great team who are embracing this new model and rising to the challenge” said Dr. Juran Kato, President and CEO of GEXVal.
For future information, please contact us: